Drug
Ivarmacitinib
Ivarmacitinib: highest development phase Post-Market, developed by Jiangsu Hengrui Medicine. 1 trial record tracked on RxWires.
- Highest phase
- Post-Market
- Developer
- Jiangsu Hengrui Medicine
Trials
| Drug | Phase | Indication |
|---|---|---|
| Ivarmacitinib NCT07452445 | Post-Market | Rheumatoid Arthritis |
Latest
No recent events.
Follow Ivarmacitinib on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.